JOINT FILING AGREEMENTJoint Filing Agreement • September 8th, 2017 • 10X Fund, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, each of the undersigned agrees that a single joint Schedule 13D and any amendments thereto may be filed on behalf of each of the undersigned with respect to the securities held by each of them in Galectin Therapeutics, Inc.
SETTLEMENT AGREEMENT AND RELEASESettlement Agreement and Release • December 1st, 2023 • 10X Fund, L.P. • Pharmaceutical preparations • Georgia
This Settlement Agreement and Release (this “Agreement”) is entered into between Galectin Therapeutics, Inc., a Nevada corporation (the “Company”) and 10X Fund, LP, a Delaware Limited Partnership (“10X Fund” as of December 17, 2018 (the “Effective Date”):
